GIP受体拮抗剂可消除部分肢端肥大症患者的矛盾性生长激素分泌
25例初治肢端肥大症患者分别在接受安慰剂和GIP受体拮抗剂GIP(3-30)NH2输注时进行口服葡萄糖耐量试验。7例存在矛盾性生长激素分泌,其中4例在GIP(3-30)NH2输注后矛盾性分泌完全消失(P=.0003),这4例中3例available的生长激素细胞腺瘤均高表达GIPR。腺瘤大小在有无矛盾性分泌的患者间无差异。
要点
- 25例初治肢端肥大症患者中7例在OGTT期间出现矛盾性GH分泌。
- GIP(3-30)NH2输注使4/7例的矛盾性GH分泌完全消失(P=.0003)。
- 3例可获取的生长激素细胞腺瘤均高表达GIPR,提示治疗靶点。
核心结论
- 25例肢端肥大症患者中7例在OGTT期间出现矛盾性GH分泌,药物性GIPR阻断在4例中消除了该分泌。
- 相应的生长激素细胞腺瘤高表达GIPR,提示该患者亚群的治疗靶点。
- 体外和离体分析证实了GIP的作用及拮抗剂的效果。
研究设计与样本
- 共纳入25例初治肢端肥大症患者,每例分别在接受安慰剂输注和GIP(3-30)NH2输注时各进行一次OGTT。
- 在基线及输注后定期采血测GH;通过磁共振成像评估垂体腺瘤大小,对切除的生长激素细胞腺瘤行免疫组化检测GIPR表达。
- 采用体外和离体方法进行机制验证;主要结局指标为GIP(3-30)NH2对OGTT期间矛盾性GH分泌的影响,以反映GIP的参与程度。
主要发现
- 7例存在矛盾性GH分泌的患者中,4例在GIP(3-30)NH2输注后矛盾性反应完全消失(P=.0003)。
- 这4例中3例可获取生长激素细胞,均显示丰富的GIPR表达。
- 有无矛盾性GH分泌的患者之间腺瘤大小无差异。
- 体外和离体分析证实了GIP的作用及拮抗剂的效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: About 30% of patients with active acromegaly experience paradoxically increased growth hormone (GH) secretion during the diagnostic oral glucose tolerance test (OGTT). Endogenous glucose-dependent insulinotropic polypeptide (GIP) is implicated in this paradoxical secretion. OBJECTIVE: We used the GIP receptor (GIPR) antagonist GIP(3-30)NH2 to test the hypothesis that GIP mediates this paradoxical response when GIPR is abundantly expressed in somatotropinomas. METHODS: A total of 25 treatment-naive patients with acromegaly were enrolled. Each patient underwent one OGTT during simultaneous placebo infusion and one OGTT during a GIP(3-30)NH2 infusion. Blood samples were drawn at baseline and regularly after infusions to measure GH. We assessed pituitary adenoma size by magnetic resonance imaging and GIPR expression by immunohistochemistry on resected somatotropinomas. For mechanistic confirmation, we applied in vitro and ex vivo approaches. The main outcome measure was the effect of GIP(3-30)NH2 on paradoxical GH secretion during OGTT as a measure of GIP involvement. RESULTS: In 4 of 7 patients with paradoxical GH secretion, GIP(3-30)NH2 infusion completely abolished the paradoxical response (P = .0003). Somatotrophs were available from 3 of 4 of these patients, all showing abundant GIPR expression. Adenoma size did not differ between patients with and without paradoxical GH secretion. CONCLUSION: Of 25 patients with acromegaly, 7 had paradoxical GH secretion during OGTT, and pharmaceutical GIPR blockade abolished this secretion in 4. Corresponding somatotroph adenomas abundantly expressed GIPR, suggesting a therapeutic target in this subpopulation of patients. In vitro and ex vivo analyses confirmed the role of GIP and the effects of the antagonist.
引用
- Jensen MH, Gasbjerg LS, Skov-Jeppesen K, et al. GIP Receptor Antagonism Eliminates Paradoxical Growth Hormone Secretion in Some Patients With Acromegaly. J Clin Endocrinol Metab. 2025. PMID: 39172542. doi:10.1210/clinem/dgae583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。